Long-term safety study of a blood protein for Alpha-1
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study checks how safe a prescribed blood protein medicine (alpha-1 proteinase inhibitor) is over the long term in people with Alpha-1 antitrypsin deficiency. You may join if you already finished an earlier study or if your lung function has been declining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have finished the earlier Alpha-1 study (including the late study visits) OR your lung function declined enough during that study
- You can sign an informed consent form and understand the study
- You must be able to complete chest CT scans (not too claustrophobic and physically able to fit in the scanner)
- You cannot have severe major ongoing illnesses like severe heart failure or liver cirrhosis
- You must not have current cancer expected to limit survival to under 1 year
- You must not have new metal in your body that could interfere with CT images
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This trial tests a medicine called alpha-1 antitrypsin given through an IV to people hospitalized with a serious COPD exacerbation. The goal is to see if it helps them recover faster.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
Hear when a new Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.